LIMASSOL, Cyprus, July 30, 2025 (GLOBE NEWSWIRE) -- Castor Maritime Inc. (NASDAQ: CTRM), (“Castor” or the “Company”), a diversified global shipping and energy company, announces that on July 29, 2025, it successfully completed a sale and leaseback transaction for the M/V Magic Thunder, a 2011-built Kamsarmax bulk carrier vessel with a Japanese counterparty. The bareboat financing amounts to $14.6 million, has a duration of five years, and a purchase option for the Company, beginning at the end of the second ...

Core Insights - Performance Shipping Inc. reported a net income of $9.1 million for Q2 2025, a decrease from $10.2 million in Q2 2024, with earnings per share of $0.69 and $0.23 for basic and diluted shares respectively [1][14] - Revenue for Q2 2025 was $18.1 million, down from $20.5 million in Q2 2024, primarily due to reduced ownership days following the sale of a vessel [2][12] - The average time-charter equivalent (TCE) rate increased to $32,295 per day in Q2 2025 from $30,970 in Q2 2024, despite operating a smaller fleet [2][5] Financial Performance - For the six months ended June 30, 2025, net income was $38.5 million, compared to $21.6 million for the same period in 2024, with earnings per share of $3.02 and $1.00 for basic and diluted shares respectively [3][14] - Net cash provided by operating activities was $11.3 million in Q2 2025, down from $14.4 million in Q2 2024 [2][28] - The company had a cash position of approximately $192 million at the end of the quarter, bolstered by a $100 million bond offering [7] Market Conditions - The tanker market remained firm in Q2 2025, supported by steady ton-mile demand and increased volatility due to geopolitical tensions [4] - The average Aframax tanker charter rate was $42,765 per day in Q2 2025, reflecting a 16% year-over-year decline from $51,140 in Q2 2024 [5][10] - Global oil consumption rose to 103.2 million barrels per day, up 1.0% from the previous quarter, while global oil production decreased to 104.5 million barrels per day, down 1.1% from the previous quarter [13] Fleet and Operational Strategy - The company is focused on fleet renewal and expansion, aiming to acquire a younger and more environmentally sustainable fleet through newbuilding and selective acquisitions [6] - As of July 29, 2025, the company had 12,432,158 common shares outstanding, along with various warrants for common shares [8][9] - The fleet utilization rate was reported at 100% for Q2 2025, indicating efficient deployment of available vessels [14]

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced the results of their new national Women in the Workplace research conducted in partnership with Dynata, the world’s largest first-party data company for insights, activation, and measurement. The study reveals a persistent gap between what employees want from their women’s health benefits, and what employers believe they are providing. Specifically, resul ...

Core Viewpoint - Genius Group Limited has completed the acquisition of Entrepreneur Resorts Ltd, integrating its entrepreneur cafés and resorts into Genius Group to expand its Genius City model [1][2]. Acquisition Details - The Asset Purchase Agreement (APA) received overwhelming support from ERL shareholders, with 99.97% voting in favor [2]. - The acquisition allows for the transfer of 50 million shares held in escrow to ERL, with a private placement transaction planned [3]. Post-Acquisition Plans - The APA enables accelerated growth plans for the combined entity, focusing on developing learning communities through the Genius Resort and Genius City models [4]. - Genius Group aims to launch 20 Genius Resorts in the next five years, targeting an average revenue of $5 million per resort [5]. - The company plans to establish 100 licensed Genius Cities, each with an average revenue goal of $1 million, and 5 owner-managed Genius Cities with an average revenue goal of $20 million [6]. Revenue Guidance - Following the APA announcement, Genius Group increased its 2025 revenue guidance by 50%, from $10 million to a range of $15 million to $18 million [7][9]. Educational and Hospitality Expertise - Genius Group's educational initiatives are powered by an AI-driven platform, while Genius Resorts will focus on building learning communities led by experts in education and hospitality [8]. Company Overview - Genius Group serves 5.8 million users globally, providing AI-powered education and acceleration solutions [10]. - Entrepreneur Resorts Ltd focuses on creating environments for entrepreneurs to co-work, co-learn, and co-live in attractive locations [12].

Netanya, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Silynxcom Ltd. (NYSE American: SYNX) ("Silynxcom" or the "Company"), a manufacturer and developer of ruggedized tactical communication headset devices, today announced it has received its first purchase order from the Israel Defense Forces (“IDF”) for a newly enhanced tactical communication system. This initial order reflects Silynxcom’s deep and ongoing relationship with the IDF, which continues to use the Company’s advanced communication technologies for ...

Diverse Use Cases May Signal Broad Demand & ApplicabilityVANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in next-generation agentic software systems, shared an update on the first three months of the commercial availability of its enterprise intelligence platform, Genius. “We believe the diversity of use cases for Genius can unlock even more value and validate that Genius fills a ...

Core Insights - VENU Holding Corporation is redefining ownership in live entertainment through a unique business model that combines upscale venues with premium hospitality and real estate opportunities [3][4] - The company aims to operate 20 venues with a total of 250,000 seats by 2028, with current operations in Colorado Springs and Gainesville, and additional venues under development [7][8] - VENU's non-dilutive growth strategy focuses on protecting shareholder equity by utilizing asset-backed lending and internally generated income, recently securing $200 million in financing [5][10] Business Model - VENU operates a "vertically integrated live entertainment" model, controlling all aspects from real estate to food and beverage operations, which allows for multiple revenue streams [4][9] - The Luxe FireSuites program offers investors ownership opportunities within venues, generating recurring revenue and targeting double-digit annual returns [6][10] - The company leverages Public-Private Partnerships (PPPs) to negotiate land contributions and tax incentives, enhancing economic impact for cities [9] Financial Performance - In 2024, VENU sold $77.7 million in FireSuites, a 250% increase from the previous year, with a target of $200 million in sales for 2025 [8][10] - The company anticipates becoming EBITDA-positive in 2026 and achieving net profitability in 2027, supported by the operational leverage from its business model [13] Market Strategy - VENU targets high-growth secondary markets with strong population trends and limited access to premium live entertainment, such as McKinney and El Paso [12] - The construction timeline for new venues is approximately 12-14 months, with many becoming cash-flow positive in their first full season due to pre-sales and secured naming rights [12] Leadership and Vision - The company emphasizes discipline in leadership, focusing on real assets and recurring income to build a sustainable business [14] - VENU's leadership is committed to long-term growth, with plans for national expansion and new revenue streams under the guidance of newly appointed President of Growth and Strategy, Terri Liebler [14][15]

Core Insights - BrainsWay is launching two new Continuing Medical Education (CME) courses to enhance clinician knowledge and confidence in Transcranial Magnetic Stimulation (TMS) [1][2] - The courses are designed to clarify the differences between BrainsWay's Deep TMS™ technology and first-generation TMS, while providing practical guidance for clinical integration [1][3] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, focusing on its proprietary Deep TMS™ platform technology [5] - The company has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [5] - BrainsWay aims to increase global awareness and access to Deep TMS, with ongoing clinical trials for various psychiatric, neurological, and addiction disorders [5] Educational Initiatives - The CME courses are supported by independent educational grants from BrainsWay and offer up to 0.5 AMA PRA Category 1 Credits™ [2] - The courses are accessible online to a wide range of healthcare professionals, including psychiatrists and nurse practitioners [2] - The first course focuses on evidence-based data supporting TMS and its role in mental health treatment, while the second course emphasizes practical strategies for patient identification and treatment integration [6]

Core Insights - Atos successfully delivered a comprehensive suite of digital services, including the AI-powered GAUDI content repository, for the European Youth Olympic Festival (EYOF) Skopje 2025, enhancing efficiency, accessibility, engagement, and security for all stakeholders involved [1][6][8] Digital Services Provided - Atos implemented a cloud-based Entries & Accreditation System that streamlined management processes and registered over 4000 participants across two simultaneous events [2] - The official Skopje 2025 website served as a central portal for event information, including schedules, results, and volunteer details, ensuring comprehensive engagement for visitors [3] - A mobile app was developed to keep users informed with the latest news, competition schedules, and exclusive content, enhancing user experience during the event [4] GAUDI Content Repository Features - GAUDI offers an AI-powered platform for managing and accessing digital content, allowing users to request content through natural language queries and providing ready-to-use video clips [5] - The system automatically generates clips and highlights, creates ready-to-share posts, adapts content for various devices, and integrates photos, enhancing the overall experience for users [6] Company Background and Experience - Atos has over 30 years of experience in serving partners and customers in major events, demonstrating flexibility and technology excellence across various scales of events [8] - The company has been involved with the Olympic Movement since 1992 and is the Official Digital Technology Partner for multiple prestigious sporting events, showcasing its long-standing commitment to the sports industry [9][11]

Core Viewpoint - Moleculin Biotech, Inc. has received a Notice of Intent to Grant for a European patent that will enhance its market position for Annamycin, a potential first non-cardiotoxic anthracycline, aimed at treating hard-to-treat tumors and viruses [2][3][4] Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses, with its lead program being Annamycin [5] - Annamycin is designed to avoid multidrug resistance and lacks the cardiotoxicity associated with current anthracyclines, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases [5] Patent and Development - The new European patent will cover methods for creating a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term extending until 2040 [3][4] - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung metastases, as well as Orphan Drug Designation from the EMA [4] Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML, following a successful Phase 1B/2 study [6] - The development pathway for Annamycin is considered substantially de-risked with input from the FDA [6] Additional Developments - Moleculin is also developing WP1066, an immune/transcription modulator targeting various cancers, and a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses and certain cancer indications [7]